Radiotherapy treatment planning for testicular seminoma

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages

  Wilder, Richard B ^a   Buyyounouski, Mark K ^b   Efstathiou, Jason A ^c   Beard, Clair J ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dose; Field; Radiotherapy; Seminoma; Testicular

Indexed keywords

4-CYCLE; ADJUVANT RADIOTHERAPY; ADJUVANT TREATMENT; ANTEROPOSTERIOR; AREA UNDER THE CURVES; BLEOMYCINS; BLOCK EDGES; CARBOPLATIN; CIS-PLATIN; CLINICAL STUDY; DOSE; ETOPOSIDE; FIELD; INFLAMMATORY BOWEL DISEASE; MAPPING STUDIES; NORMAL TISSUE; RADIATION EXPOSURE; RADIOTHERAPY TREATMENT PLANNING; SEMINOMA; TESTICULAR; TESTICULAR SEMINOMA; THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY; VERTEBRAL BODY;

CHEMOTHERAPY; PATIENT MONITORING; PLATINUM COMPOUNDS; RADIOTHERAPY; TISSUE; TOXICITY;

THREE DIMENSIONAL;

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ACETABULUM; ADJUVANT THERAPY; ANATOMY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; CONSULTATION; DRUG EFFICACY; DRUG TOLERABILITY; ENTERITIS; FOLLOW UP; HORSESHOE KIDNEY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY; LUMBAR VERTEBRA; LYMPHADENOPATHY; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RECURRENCE FREE SURVIVAL; REVIEW; SECOND CANCER; SEMINOMA; SPERMATOZOON COUNT; SUPINE POSITION; TESTIS; TREATMENT PLANNING; TUMOR VOLUME; VERTEBRA BODY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHATIC DISEASES; MALE; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 84862640790     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.044     Document Type: Review

References (67)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2. McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003;97:63-70.
3. Weir HK, Marrett LD, Moravan V. Trends in the incidence of testicular germ cell cancer in Ontario by histologic subgroup, 1964-1996. CMAJ 1999;160:201-205.
4. Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: Patterns of relapse and follow-up. J Natl Cancer Inst 2011;103:241-249.
5. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-1365.
6. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 2010;28:4649-4657.
7. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-1523.
8. Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640-647.
9. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 2002;20:4448-4452.
10. Chung P, Warde P. Stage I seminoma: Adjuvant treatment is effective but is it necessary? J Natl Cancer Inst 2011;103:194-196.
11. Chung PW, Daugaard G, Tyldesle S, et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study (Abstr.). J Clin Oncol 2010;18(Suppl.):15S.
12. Aparicio J, Maroto P, Del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: The third Spanish Germ Cell Cancer Group study. J Clin Oncol 2011;29:4677-4681.
13. Bosl GJ, Patil S. Carboplatin in clinical stage I seminoma: Too much and too little at the same time. J Clin Oncol 2011;29:949-952.
14. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 2008;53:497-513.
15. Schmoll HJ, Jordan K, Huddart R, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):v140-v146.
16. Warde P, Gospodarowicz M. Evolving concepts in stage I seminoma. BJU Int 2009;104:1357-1361.
17. Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 2010;4:e19-e38.
18. Stephenson AJ. Current treatment options for clinical stage I seminoma. World J Urol 2009;27:427-432.
19. Yoney A, Yildirim C, Isikli L, et al. Radiotherapy for stage I seminoma of the testis. Indian J Cancer 2010;47:179-183.
20. Classen J, Schmidberger H, Meisner C, et al. Para-aortic irradiation for stage I testicular seminoma: Results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 2004;90:2305-2311.
21. Martin JM, Joon DL, Ng N, et al. Towards individualised radiotherapy for Stage I seminoma. Radiother Oncol 2005;76:251-256.
22. Boujelbene N, Cosinschi A, Khanfir K, et al. Pure seminoma: A review and update. Radiat Oncol 2011;6:90.
23. Zilli T, Boudreau C, Doucet R, et al. Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma. Acta Oncol 2011;50:555-562.
24. Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-88.
25. Simone CB 2nd, Kramer K, O'Meara WP, et al. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys 2012;82:242-249.
26. Efstathiou JA, Paly JJ, Lu H, et al. Adjuvant radiation therapy for early-stage seminoma: Proton-photon comparison and second cancer risk (Abstr.). J Clin Oncol 2011;29(7 Suppl):228.
27. Zietman A, Goitein M, Tepper JE. Technology evolution: Is it survival of the fittest? J Clin Oncol 2010;28:4275-4279.
28. Viamonte MR. Atlas of lymphography. New York: Thieme-Stratton; 1980.
29. Taylor A, Rockall AG, Reznek RH, et al. Mapping pelvic lymph nodes: Guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:1604-1612.
30. Shih HA, Harisinghani M, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 2005;63:1262-1269.
31. Dinniwell R, Chan P, Czarnota G, et al. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009;74:844-851.
32. McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases from pelvic tumors: Anatomic classification, characterization, and staging. Radiology 2010;254:31-46.
33. Vilarino-Varela MJ, Taylor A, Rockall AG, et al. A verification study of proposed pelvic lymph node localisation guidelines using nanoparticle-enhanced magnetic resonance imaging. Radiother Oncol 2008;89:192-196.
34. Albers P, Albrecht W, Algaba F, et al., eds. Guidelines on testicular cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/ 10-Testicular-Cancer.pdf. Updated March 2011. Accessed October 21, 2011.
35. Detti B, Livi L, Scoccianti S, et al. Management of Stage II testicular seminoma over a period of 40 years. Urol Oncol 2009;27:534-538.
36. Heidenreich A, Bokemeyer C, Souchon R. [Stage-specific treatment for testicular germ cell tumours]. Urologe A 2009;48:377-385.
37. Missett B, Gottschalk AR. Testicular cancer. In: Hansen EK, Roach III M, editors. Handbook of evidence-based radiation oncology. 1st ed. New York: Springer; 2007. p. 325-334.
38. Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: Final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:1101-1106.
39. Domont J, Massard C, Patrikidou A, et al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol. In press.
40. Garcia-del-Muro X, Maroto P, Guma J, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: A Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008;26:5416-5421.
41. Saxman SB, Finch D, Gonin R, et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indian University experience. J Clin Oncol 1998;16:702-706.
42. Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 1997;15:2553-2558.
43. Grimison PS, Stockler MR, Thomson DB, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: Updated analysis of a randomized trial. J Natl Cancer Inst 2010;102:1253-1262.
44. Morton GC, Thomas GM. Testis. In: Perez CA, Brady LW, Halperin EC, et al., editors. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2004. p. 1763-1784.
45. Alomary I, Samant R, Gallant V. Treatment of stage I seminoma: A 15-year review. Urol Oncol 2006;24:180-183.
46. Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: Is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 1999;50:349-353.
47. Chung PW, Warde PR, Panzarella T, et al. Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 2003;56:746-748.
48. Hanks GE, Peters T, Owen J. Seminoma of the testis: Long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992;24:913-919.
49. Lederman GS, Sheldon TA, Chaffey JT, et al. Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987;60:772-776.
50. Thomas GM, Rider WD, Dembo AJ, et al. Seminoma of the testis: Results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 1982;8:165-174.
51. Garmezy B, Pagliaro LC. Choosing treatment for stage I seminoma: Who should get what? Oncology (Williston Park) 2009;23:753. 759.
52. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200-1208.
53. Niewald M, Freyd J, Fleckenstein J, et al. Low-dose radiotherapy for Stage I seminoma - long-term results. Int J Radiat Oncol Biol Phys 2006;66:1112-1119.
54. Khoo VS, Rainford K, Horwich A, et al. The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: A randomized pilot study. Clin Oncol (R Coll Radiol) 1997;9:252-257.
55. Fossa SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: Treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383-388.
56. Bruns F, Bremer M, Meyer A, et al. Adjuvant radiotherapy in stage I seminoma: Is there a role for further reduction of treatment volume? Acta Oncol 2005;44:142-148.
57. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999;17:1146.
58. OzRadOnc: A collection of thoughts and notes. Radiotherapy-OzRadOnc Web site. http://ozradonc.wikidot.com/me-seminomaradiotherapy. Accessed October 21, 2011.
59. Pearse M, Morton GC. Testicular cancer. In: Levitt SH, Purdy JA, Perez CA, et al., editors. Technical basis of radiation therapy: Practical clinical applications. 4th revised ed. Berlin: Springer-Verlag; 2008. p. 739-753.
60. Zwahlen DR, Martin JM, Millar JL, et al. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2008;70:853-858.
61. Paly J, Efstathiou JA, Hedgire SS, et al. Mapping patterns of nodal metastases in seminoma: Rethinking the para-aortic field (Abstr.). Int J Radiat Oncol Biol Phys 2011;81:S44.
62. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-1399.
63. Teh BS, Paulino AC, Butler EB. Testicular cancer. In: Lu JJ, Brady LW, editors. Radiation oncology: An evidence-based approach. Berlin: Springer-Verlag; 2008. p. 321-328.
64. Bamberg M, Schmidberger H, Meisner C, et al. Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 1999;83:823-827.
65. Schmidberger H, Bamberg M, Meisner C, et al. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: A prospective multicenter study. Int J Radiat Oncol Biol Phys 1997;39:321-326.
66. Alexander EJ, White IM, Horwich A. Update on management of seminoma. Indian J Urol 2010;26:82-91.
67. Chavaudra J, Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62. Cancer Radiother 2001;5:472-478.